- Home
- URGN vs BJRI Comparison
URGN vs BJRI Comparison
Compare URGN & BJRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- BJRI
- Stock Information
- Founded
- URGN 2004
- BJRI 1978
- Country
- URGN United States
- BJRI United States
- Employees
- URGN N/A
- BJRI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- BJRI Restaurants
- Sector
- URGN Health Care
- BJRI Consumer Discretionary
- Exchange
- URGN Nasdaq
- BJRI Nasdaq
- Market Cap
- URGN 831.6M
- BJRI 983.0M
- IPO Year
- URGN 2017
- BJRI 1996
- Fundamental
- Price
- URGN $19.22
- BJRI $36.72
- Analyst Decision
- URGN Strong Buy
- BJRI Hold
- Analyst Count
- URGN 8
- BJRI 5
- Target Price
- URGN $29.00
- BJRI $41.40
- AVG Volume (30 Days)
- URGN 1.3M
- BJRI 516.0K
- Earning Date
- URGN 08-07-2025
- BJRI 07-31-2025
- Dividend Yield
- URGN N/A
- BJRI N/A
- EPS Growth
- URGN N/A
- BJRI N/A
- EPS
- URGN N/A
- BJRI 0.95
- Revenue
- URGN $91,871,000.00
- BJRI $1,367,941,000.00
- Revenue This Year
- URGN $39.80
- BJRI $5.50
- Revenue Next Year
- URGN $108.94
- BJRI $3.00
- P/E Ratio
- URGN N/A
- BJRI $38.49
- Revenue Growth
- URGN 8.98
- BJRI 2.91
- 52 Week Low
- URGN $3.42
- BJRI $27.61
- 52 Week High
- URGN $19.69
- BJRI $47.02
- Technical
- Relative Strength Index (RSI)
- URGN 76.29
- BJRI 29.32
- Support Level
- URGN $18.37
- BJRI $35.99
- Resistance Level
- URGN $19.36
- BJRI $39.24
- Average True Range (ATR)
- URGN 1.03
- BJRI 1.31
- MACD
- URGN 0.25
- BJRI -0.47
- Stochastic Oscillator
- URGN 91.26
- BJRI 10.01
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.